Literature DB >> 27986876

Changes in insomnia subtypes in early Parkinson disease.

Lena K Tholfsen1, Jan P Larsen2, Jörn Schulz2, Ole-Bjørn Tysnes2, Michaela D Gjerstad2.   

Abstract

OBJECTIVE: To examine the development of factors associated with insomnia in a cohort of originally drug-naive patients with incident Parkinson disease (PD) during the first 5 years after diagnosis.
METHODS: One hundred eighty-two drug-naive patients with PD derived from a population-based incident cohort and 202 control participants were assessed for insomnia before treatment initiation and were repeatedly examined after 1, 3, and 5 years. Insomnia was diagnosed according to the Stavanger Sleepiness Questionnaire. The Parkinson's Disease Sleep Scale was used to differentiate sleep initiation problems from problems of sleep maintenance. Generalized estimating equation models were applied for statistical measures.
RESULTS: The prevalence of insomnia in general was not higher in patients with PD compared to controls at the 5-year follow-up. There were changes in the prevalence of the different insomnia subtypes over the 5-year follow-up. The prevalence of solitary problems in sleep maintenance increased from 31% (n = 18) in the drug-naive patients at baseline to 49% (n = 29) after 1 year and were associated with the use of dopamine agonists and higher Montgomery-Åsberg Depression Rating Scale scores. The prevalence of solitary sleep initiation problems decreased continuously from 21% (n = 12) at baseline to 7.4% (n = 4) after 5 years; these were associated with less daytime sleepiness.
CONCLUSIONS: The prevalence rates of the different insomnia subtypes changed notably in patients with early PD. The frequency of sleep maintenance problems increased, and these problems were associated with dopamine agonist use and depressive symptoms, while the total number of patients with insomnia remained stable. Our findings reflect the need for early individual assessments of insomnia subtypes and raise the possibility of intervention to reduce these symptoms in patients with early PD.
© 2016 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27986876     DOI: 10.1212/WNL.0000000000003540

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  15 in total

1.  Role of plasminogen activator inhibitor-1 in the diagnosis and prognosis of patients with Parkinson's disease.

Authors:  Hong Pan; Ying Zhao; Zhengping Zhai; Jinyu Zheng; Yong Zhou; Qijin Zhai; Xiangyang Cao; Jisha Tian; Liandong Zhao
Journal:  Exp Ther Med       Date:  2018-04-17       Impact factor: 2.447

2.  Presleep Cognitive Arousal and Insomnia Comorbid to Parkinson Disease: Evidence for a Serial Mediation Model of Sleep-Related Safety Behaviors and Dysfunctional Beliefs About Sleep.

Authors:  Cindy Lebrun; Marie-Christine Gély-Nargeot; Khaalid Hassan Maudarbocus; Alexia Rossignol; Christian Geny; Sophie Bayard
Journal:  J Clin Sleep Med       Date:  2019-09-15       Impact factor: 4.062

Review 3.  Overview of Sleep and Circadian Rhythm Disorders in Parkinson Disease.

Authors:  Priti Gros; Aleksandar Videnovic
Journal:  Clin Geriatr Med       Date:  2019-09-06       Impact factor: 3.076

Review 4.  Sleep-wake and circadian disturbances in Parkinson disease: a short clinical guide.

Authors:  Christian R Baumann
Journal:  J Neural Transm (Vienna)       Date:  2019-06-29       Impact factor: 3.575

Review 5.  Longitudinal Studies of Sleep Disturbances in Parkinson's Disease.

Authors:  Zheyu Xu; Kirstie N Anderson; Nicola Pavese
Journal:  Curr Neurol Neurosci Rep       Date:  2022-08-26       Impact factor: 6.030

6.  KLF4 Exerts Sedative Effects in Pentobarbital-Treated Mice.

Authors:  Ziqian Cheng; Wei Yang; Bingjin Li; Ranji Cui
Journal:  J Mol Neurosci       Date:  2020-08-13       Impact factor: 3.444

7.  SLEEP AND CIRCADIAN RHYTHM DISORDERS IN PARKINSON'S DISEASE.

Authors:  Priti Gros; Aleksandar Videnovic
Journal:  Curr Sleep Med Rep       Date:  2017-07-06

Review 8.  Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson's Disease.

Authors:  Reyisha Taximaimaiti; Xingguang Luo; Xiao-Ping Wang
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

Review 9.  Practical Evaluation and Management of Insomnia in Parkinson's Disease: A Review.

Authors:  Douglas M Wallace; William K Wohlgemuth; Lynn Marie Trotti; Amy W Amara; Irene A Malaty; Stewart A Factor; Sagarika Nallu; Lara Wittine; Robert A Hauser
Journal:  Mov Disord Clin Pract       Date:  2020-02-03

10.  Insomnia symptom subtypes and manifestations of prodromal neurodegeneration: a population-based study in the Canadian Longitudinal Study on Aging.

Authors:  Chun W Yao; Amélie Pelletier; Seyed-Mohammad Fereshtehnejad; Nathan Cross; Thanh Dang-Vu; Ronald B Postuma
Journal:  J Clin Sleep Med       Date:  2022-02-01       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.